Ugandan firm files seven US patents for new mRNA cancer vaccine
Ugandan biotechnology firm Dei BioPharma has filed seven US patents for a modular mRNA cancer vaccine platform. The technology aims to create pre-manufactured vaccines matched to specific molecular events in tumors rather than just the organ of origin.
Why it matters
This development represents a significant step for African biotechnology in the global effort to create scalable, off-the-shelf cancer immunotherapies.
Ugandan biotechnology firm Dei BioPharma has filed seven groundbreaking patents in the United States covering a modular portfolio of messenger RNA (mRNA) cancer-vaccine technologies.
Dei BioPharma's application, spearheaded by its founder Dr Matthias Magoola, positions the firm as a locally anchored programme within the global effort to develop off-the-shelf cancer immunotherapies.
The firm said in a statement that the seven-application US patent portfolio establishes a molecularly organized framework for pre-manufactured, HLA-matched mRNA vaccine candidates.
This, it said, speaks directly to its long-term objective of building a platform broad enough to address major cancer-causing molecular events across many patient subgroups.
"The filings span recurrent fusion junctions, driver mutations, tumor-specific frameshifts, viral oncoproteins and an omnibus architecture designed to support multiple target-defined products," reads part of the August 26 statement.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in